Table 1.
Patient’s clinical and histopathologic characteristics
| Number of patients, n (%) | Subset with FU, n (%) | ||
|---|---|---|---|
| Total | 122 (100.0) | 77 (100.0) | |
| Histologic subtype | ccRCC | 86 (70.5) | 57 (74.0) |
| pap. RCC | 24 (19.7) | 17 (22.1) | |
| chrom. RCC | 3 (2.5) | 2 (2.6) | |
| Mixed histology | 5 (4.1) | 1 (1.3) | |
| Other | 4 (3.3) | 0 (0) | |
| Gender | Female | 43 (35.2) | 27 (35.1) |
| Male | 79 (64.8) | 50 (64.9) | |
| Age (years) | Median | 64.5 | 65 |
| Min-Max | 35–91 | 37–91 | |
| Metastasis | M0 | 95 (77.9) | 59 (76.6) |
| M1 | 27 (22.1) | 18 (23.4) | |
| NA | 0 (0.0) | ||
| Lymph node status | N0 | 107 (87.7) | 70 (90.9) |
| N1 | 15 (12.3) | 7 (9.1) | |
| Tumor stage | pT1 | 11 (9.0) | 8 (10.4) |
| pT1a | 35 (28.7) | 24 (31.2) | |
| pT1b | 21 (17.2) | 13 (16.9) | |
| pT2 | 8 (6.6) | 6 (7.8) | |
| pT3 | 5 (4.1) | 2 (2.6) | |
| pT3a | 12 (9.8) | 4 (5.2) | |
| pT3b | 25 (20.5) | 18 (23.4) | |
| pT3c | 3 (2.5) | 2 (2.6) | |
| pT4 | 1 (0.8) | 0 (0.0) | |
| NA | 1 (0.8) | 0 (0.0) | |
| Differentiation | G1 | 24 (19.7) | 14 (18.2) |
| G1–2 | 16 (13.1) | 10 (13.0) | |
| G2 | 62 (50.8) | 42 (54.5) | |
| G2–3 | 9 (7.4) | 5 (6.5) | |
| G3 | 11 (9.0) | 6 (7.8) | |
| State of disease* | Localized | 65 (53.3) | 42 (54.5) |
| Advanced | 56 (45.9) | 35 (45.5) | |
| NA | 1 (0.8) | 0 (0.0) |
Abbreviations: ccRCC clear cell renal cell carcinoma (RCC); pap. RCC papillary RCC; chrom. RCC chromophobe RCC; FU follow-up; NA not available
*Localized disease defined as pT ≤ 2, N0, M0; Advanced disease defined as pT ≥ 3 and/or N+, M+